1 Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population Ingo K Mellinghoff 1 , Katherine B Peters 2 , Timothy F Cloughesy 3 , Howard A Burris III 4 , Elizabeth A Maher 5 , Filip Janku 6 , Gregory M Cote 7 , Macarena I De La Fuente 8 , Jennifer L Clarke 9 , Kha Le 10 , Rachel Guo 10 , Man Yuen 10 , Marissa Arnofsky 10 , Islam Hassan 10 , Lori Steelman 10 , Shuchi S Pandya 10 , Patrick Y Wen 11 1 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2 Duke University Medical Center, Durham, NC, USA; 3 University of California Los Angeles, Los Angeles, CA, USA; 4 Sarah Cannon Research Institute, Nashville, TN, USA; 5 University of Texas Southwestern Medical Center, Dallas, TX, USA; 6 University of Texas MD Anderson Cancer Center, Houston, TX, USA; 7 Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; 8 Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; 9 University of California San Francisco, San Francisco, CA, USA; 10 Agios Pharmaceuticals, Inc., Cambridge, MA, USA; 11 Dana-Farber/Harvard Cancer Center, Boston, MA, USA Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Format, May 29–31, 2020 2504